Navigation Links
ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance
Date:5/2/2008

tements about future financial and operating results and liquidity needs, anticipated revenue synergies and cost savings as a result of ev3's acquisition of FoxHollow and the timing thereof, anticipated expenses as a result of ev3's acquisition of FoxHollow and the timing thereof, effects of recent U.S. peripheral vascular sales force restructuring activities, new product benefits and market acceptance, and other statements identified by words such as "expect," "anticipate," "will," "may," "believe," "could," "outlook," "guidance," or words of similar meaning and any other statements that are not historical facts. Such forward-looking statements are based upon the current beliefs and expectations of ev3's management and are inherently subject to risks and uncertainties that could cause actual results to differ materially from those projected or implied. Such potential risks and uncertainties include, but are not limited to, in no particular order: the failure to achieve profitability within expected time periods, the failure to realize revenue synergies and cost-savings from ev3's acquisition of FoxHollow, the closure of its Redwood City facility or delay in realization thereof; the businesses of ev3 and FoxHollow not being integrated successfully, or such integration taking longer or being more difficult, time- consuming or costly to accomplish than expected; the impact of competitive products and pricing; changes in the regulatory environment; availability of third party reimbursement; potential margin pressure resulting from volume selling, as well as potential adverse effects on future product demand resulting from volume purchases; delays in regulatory approvals and the introduction of new products; market acceptance of new products and success of clinical testing. More detailed information on these and additional factors which could affect ev3's operating and financial results is described in the company's filings with the Securities and Exchange Commission, i
'/>"/>
SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... This webinar will focus on EMA ... assessment in biosimilars. , Regulatory frameworks are evolving many ... however the complex nature of biopharmaceuticals makes the demonstration ... extremely challenging. Based on the specific aspects of biosimilar ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... January 15, 2014 The Microcompetition with Foreign ... disease. One of these latent viruses is the Epstein Barr ... (RA). Rheumatoid arthritis (RA) is a chronic inflammatory disease that ... study found that RA patients have high concentrations of EBV ...
(Date:1/15/2014)... 2013 was a banner year of continued innovation ... continued independent research led by the team at Wake ... million grant from the Susanne Marcus Collins Foundation, had ... reviewed journal, Amy Grant highlighted Brainwave Optimization® in First ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3
... -- Sinovac Biotech Ltd.,(NYSE Alternext US: SVA), ... today,announced its wholly owned subsidiary, Tangshan Yian ... China,s Ministry of Agriculture to,conduct field trials ... with independent intellectual property rights. With this ...
... 26 MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) ... efficacy portion of its initial Phase 3 clinical,trial evaluating ... acute treatment of migraine. , ... potential to be,both fast acting and long-lasting, providing pain ...
... second of its "next-generation" health and longevity products ... cardiovascular healthNEW YORK, Jan. 26 AIM Pharmakon, ... the introduction of the next generation of health ... premium-quality liquid calcium mineral concentrate for bone development ...
Cached Biology Technology:Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 2Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 3Sinovac Enters Veterinary Vaccine Market with Inactivated Rabies Vaccine 4MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 2MAP Pharmaceuticals Announces Completion of Enrollment in Phase 3 Clinical Trial of MAP0004 in Patients with Migraine 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 2AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 3AIM Pharmakon (API) Announced a New Proprietary Premium-Quality Natural Concentrated Liquid Calcium and Mineral Supplement Now Available Direct to Consumers 4
(Date:7/9/2014)... ability to switch out one gene for another in ... from science fiction to reality within this decade. As ... promise--the hope of fixing disease-causing genes in humans, for ... scientists have put one of those concerns to rest: ... overall occurrence of mutations in the cells. The new ...
(Date:7/9/2014)... Sexual selection refers to species, selection for traits ... type of natural selection enhances opportunities to mate, the ... Biologists at the University of California, Riverside have now ... of a placenta are linked. Describing the life ... the family Poeciliidae, the researchers found that species with ...
(Date:7/9/2014)... Cancer Genome Atlas (TCGA) Research Network have identified ... lung adenocarcinoma, the most common subtype of lung ... the number of possible therapeutic targets for this ... patients with treatable mutations because many potent cancer ... TCGA is jointly funded and managed by the ...
Breaking Biology News(10 mins):No extra mutations in modified stem cells, study finds 2No extra mutations in modified stem cells, study finds 3Biologists link sexual selection and placenta formation 2Biologists link sexual selection and placenta formation 3Biologists link sexual selection and placenta formation 4Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3
... from the Andes in Colombia to the Atlantic in ... plains of the Llanos and the Guiana shield ... 3rd most important river system on the planet, and one of ... has shown a strong commitment to the achievement of the ...
... citizens negotiated the tensions following the March 4 nationwide ... 2007 vote weighed heavily for many reasons. Among those ... of a new paper in AIDS Reviews , ... do to public health by disrupting treatment and thereby ...
... is an exotic plant originating from the Ukraine and ... Ontario, Canada. It has been found growing successfully in ... edges and understories, parks, road edges and railway embankments. ... large and dense stands that climb over other plants. ...
Cached Biology News:The natural ecosystems in the Colombian Orinoco Basin are in danger 2Political strife undermines HIV treatment 2Political strife undermines HIV treatment 3A European invader outcompetes Canadian plants even outside its usual temperature range 2
One-step, microplate or cuvet, colorimetric, detection range 0.78 ug/dL to 65 ug/dL Zn in serum, plasma, urine, saliva etc. Procedure: 10 min....
Zebrafish Ephrin-B2 Biotinylated Affinity Purified PAb...
... Customer Peptide Synthesis , Containing one Phospho-Amino Acid ... returned to customer conjugation of peptide to KLH protein , ... 102 days/each , Pre-immune bleed x1 /each ... Test bleed (app. 5 ml) x1 /each ...
The Varian 4000 GC/MS system offers three easily switchable ionization configurations: internal ionization (II), external ionization (EI) or hybrid chemical ionization (CI)...
Biology Products: